MXPA01009404A - Metodo para tratar trastornos de alimentacion. - Google Patents

Metodo para tratar trastornos de alimentacion.

Info

Publication number
MXPA01009404A
MXPA01009404A MXPA01009404A MXPA01009404A MXPA01009404A MX PA01009404 A MXPA01009404 A MX PA01009404A MX PA01009404 A MXPA01009404 A MX PA01009404A MX PA01009404 A MXPA01009404 A MX PA01009404A MX PA01009404 A MXPA01009404 A MX PA01009404A
Authority
MX
Mexico
Prior art keywords
eating disorders
treating eating
treating
nervosa
snacking
Prior art date
Application number
MXPA01009404A
Other languages
English (en)
Inventor
Carl M Mendel
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22418412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA01009404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA01009404A publication Critical patent/MXPA01009404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se usa un compuesto de la formula (I): (ver formula) o una sal farmaceuticamente aceptable del mismo, donde R1 y R2 son independientes H o metilo (por ejemplo, clorhidrato de N,N-dimetil-1-[1-(4-clorofenil)ciclobutil]-3-metilbutilamina, en la forma de su monohidrato), para tratar trastornos de alimentacion, como anorexia nerviosa, bulimia nerviosa, aumento de peso despues de dejar de fumar, comer bocadillos o comer botanas.
MXPA01009404A 1999-03-19 2000-03-17 Metodo para tratar trastornos de alimentacion. MXPA01009404A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12515099P 1999-03-19 1999-03-19
PCT/US2000/007115 WO2000054765A1 (en) 1999-03-19 2000-03-17 Method of treating eating disorders

Publications (1)

Publication Number Publication Date
MXPA01009404A true MXPA01009404A (es) 2004-03-19

Family

ID=22418412

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01009404A MXPA01009404A (es) 1999-03-19 2000-03-17 Metodo para tratar trastornos de alimentacion.

Country Status (23)

Country Link
US (1) US6365633B1 (es)
EP (1) EP1178789B1 (es)
JP (1) JP2003519087A (es)
KR (1) KR100432825B1 (es)
CN (1) CN1188120C (es)
AT (1) ATE401066T1 (es)
AU (1) AU773188C (es)
BR (1) BR0009026A (es)
CA (1) CA2367666C (es)
CZ (1) CZ20013278A3 (es)
DE (1) DE60039508D1 (es)
ES (1) ES2307501T3 (es)
HK (1) HK1045455B (es)
HU (1) HUP0200495A3 (es)
IL (1) IL145240A (es)
MX (1) MXPA01009404A (es)
NO (1) NO20014479L (es)
NZ (1) NZ514011A (es)
PL (1) PL351963A1 (es)
SK (1) SK12992001A3 (es)
TR (1) TR200102646T2 (es)
WO (1) WO2000054765A1 (es)
ZA (1) ZA200107533B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006963A1 (en) * 1992-06-23 2002-01-17 Young James W. Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1784390A2 (en) * 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en) 2005-05-30 2012-03-20 Msd. K.K. Piperidine derivative
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
JPWO2007029847A1 (ja) 2005-09-07 2009-03-19 萬有製薬株式会社 二環性芳香族置換ピリドン誘導体
EP1938811A4 (en) * 2005-09-22 2008-12-17 Eisai R&D Man Co Ltd MEDICAL COMPOSITION FOR THE TREATMENT OF BULAMINE AND BULAMIC DEPRESSIONS
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
WO2007055418A1 (ja) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
MX2009007720A (es) 2007-01-16 2013-03-22 Ipintl Llc Nueva composicion para el tratamiento del sindrome metabolico.
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2007360979B2 (en) * 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
JPWO2009110510A1 (ja) 2008-03-06 2011-07-14 Ｍｓｄ株式会社 アルキルアミノピリジン誘導体
CN101981025A (zh) 2008-03-28 2011-02-23 万有制药株式会社 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MX2021005904A (es) 2018-11-20 2021-09-08 Tes Pharma S R L Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
EP0977572A1 (en) * 1997-04-24 2000-02-09 Merck Sharp & Dohme Ltd. Use of nk-1 receptor antagonists for treating eating disorders
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
JP2002535273A (ja) * 1999-01-20 2002-10-22 クノール・ゲー・エム・ベー・ハー 禁煙の支援方法
AU779248B2 (en) * 1999-02-24 2005-01-13 University Of Cincinnati, The Use of sulfamate derivatives for treating impulse control disorders

Also Published As

Publication number Publication date
EP1178789A1 (en) 2002-02-13
IL145240A (en) 2007-02-11
NO20014479L (no) 2001-11-02
WO2000054765A8 (en) 2002-05-23
EP1178789B1 (en) 2008-07-16
CN1188120C (zh) 2005-02-09
DE60039508D1 (de) 2008-08-28
HK1045455B (zh) 2009-04-09
BR0009026A (pt) 2003-03-05
JP2003519087A (ja) 2003-06-17
CZ20013278A3 (cs) 2002-07-17
CN1365276A (zh) 2002-08-21
AU773188C (en) 2006-01-05
HUP0200495A3 (en) 2004-09-28
HK1045455A1 (en) 2002-11-29
NZ514011A (en) 2001-09-28
ATE401066T1 (de) 2008-08-15
TR200102646T2 (tr) 2002-08-21
EP1178789A4 (en) 2004-02-18
CA2367666C (en) 2008-11-25
NO20014479D0 (no) 2001-09-14
ES2307501T3 (es) 2008-12-01
ZA200107533B (en) 2002-12-12
AU3894700A (en) 2000-10-04
WO2000054765A1 (en) 2000-09-21
PL351963A1 (en) 2003-07-14
KR100432825B1 (ko) 2004-05-24
IL145240A0 (en) 2002-06-30
US6365633B1 (en) 2002-04-02
HUP0200495A2 (en) 2002-08-28
CA2367666A1 (en) 2000-09-21
SK12992001A3 (sk) 2002-03-05
AU773188B2 (en) 2004-05-20
KR20020063107A (ko) 2002-08-01

Similar Documents

Publication Publication Date Title
MXPA01009404A (es) Metodo para tratar trastornos de alimentacion.
GEP20084391B (en) Pyrazoles and methods of making and using the same
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
WO2001032652A3 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
NO20012194D0 (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
AU2003239389A1 (en) Opioid receptor antagonists
MY138826A (en) 2,7-substituted indoles
WO2000056315A8 (en) Treatment of pain
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA01009464A (es) Metodo para el tratamiento de apnea de sueno.
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
BG105996A (en) Method of treating eating disorders
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
NZ504124A (en) Phenyl-alkyl-imidazoles and use in treating inflammatory disease
NO20063299L (no) Syntese av en polymorf av 4-amino-5-klor-2-metoksy-N-(1-azabisyklo[3.3.1]non-4-yl)benzamidhydrokloridhydrat
MXPA01009461A (es) Tratamiento de osteoartritis.
MXPA01009469A (es) Tratamiento para disminuir la adhesividad de las plaquetas.
MXPA03009723A (es) Procedimientos e intermediarios para preparar epoxidos substituidos de bencilo.
MXPA01009468A (es) Tratamiento de hipertension pulmonar.
MXPA01009463A (es) Tratamiento de hernia hiatial.
MXPA04004071A (es) Metodo para tratamiento de vejiga hiperactiva.
MXPA01009465A (es) Perdida de peso despues del embarazo.
EP1234576A4 (en) MEDICINE AGAINST EATING DISORDERS